Faisal Khurshid
Stock Analyst at Leerink Partners
(0.91)
# 3,606
Out of 4,670 analysts
10
Total ratings
25%
Success rate
-8.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Initiates: Outperform | $15 | $2.73 | +449.45% | 1 | Nov 4, 2024 | |
| TRVI Trevi Therapeutics | Assumes: Outperform | $7 | $2.91 | +140.55% | 1 | Sep 9, 2024 | |
| PRTC PureTech Health | Assumes: Outperform | $45 | $22.55 | +99.56% | 1 | Sep 9, 2024 | |
| PLRX Pliant Therapeutics | Assumes: Outperform | $33 | $12.98 | +154.24% | 1 | Sep 9, 2024 | |
| IRWD Ironwood Pharmaceuticals | Initiates: Market Perform | $5 | $3.44 | +45.35% | 1 | Sep 9, 2024 | |
| GLPG Galapagos NV | Initiates: Market Perform | $24 | $27.13 | -11.54% | 1 | Sep 9, 2024 | |
| GERN Geron | Initiates: Outperform | $7 | $4.07 | +71.99% | 1 | Sep 9, 2024 | |
| MNKD MannKind | Assumes: Outperform | $8 | $6.84 | +16.96% | 1 | Sep 9, 2024 | |
| KYMR Kymera Therapeutics | Assumes: Outperform | $60 | $44.98 | +33.39% | 1 | Sep 9, 2024 | |
| IMUX Immunic | Assumes: Outperform | $5 | $1.10 | +354.55% | 1 | Sep 9, 2024 |
Zura Bio
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $2.73
Upside: +449.45%
Trevi Therapeutics
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $2.91
Upside: +140.55%
PureTech Health
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $22.55
Upside: +99.56%
Pliant Therapeutics
Sep 9, 2024
Assumes: Outperform
Price Target: $33
Current: $12.98
Upside: +154.24%
Ironwood Pharmaceuticals
Sep 9, 2024
Initiates: Market Perform
Price Target: $5
Current: $3.44
Upside: +45.35%
Galapagos NV
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $27.13
Upside: -11.54%
Geron
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $4.07
Upside: +71.99%
MannKind
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $6.84
Upside: +16.96%
Kymera Therapeutics
Sep 9, 2024
Assumes: Outperform
Price Target: $60
Current: $44.98
Upside: +33.39%
Immunic
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $1.10
Upside: +354.55%